What is Zacks Research’s Estimate for Chemours Q1 Earnings?

The Chemours Company (NYSE:CC – Free Report) – Equities researchers at Zacks Research cut their Q1 2027 earnings per share (EPS) estimates for Chemours in a report released on Monday, November 16th. Zacks Research analyst Team now forecasts that the specialty chemicals company will post earnings of $0.21 per share for the quarter, down from their prior forecast of $0.40. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Chemours’ FY2027 earnings at $1.71 EPS and FY2028 earnings at $1.98 EPS.

A number of other equities research analysts have also recently issued reports on the stock. BMO Capital Markets reduced their target price on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Chemours in a report on Tuesday, November 3rd. UBS Group decreased their target price on shares of Chemours from $16.00 to $15.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 4th. Royal Bank Of Canada lowered shares of Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 target price on the stock. in a research report on Tuesday, October 13th. Finally, Morgan Stanley set a $18.00 target price on shares of Chemours in a report on Monday, August 10th. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Chemours presently has a consensus rating of “Hold” and a consensus target price of $17.36.

Read Our Latest Analysis on CC

Chemours Stock Performance

Shares of NYSE CC opened at $12.20 on Wednesday. The company has a debt-to-equity ratio of 24.25, a current ratio of 1.81 and a quick ratio of 0.98. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -11.96 and a beta of 1.47. The stock’s fifty day moving average price is $13.63 and its two-hundred day moving average price is $18.13. Chemours has a one year low of $10.44 and a one year high of $28.67.

Chemours (NYSE:CC – Get Free Report) last announced its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). The firm had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a positive return on equity of 76.52% and a negative net margin of 2.64%. Chemours’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the business posted $0.40 EPS.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be given a $0.0875 dividend. The ex-dividend date is Monday, November 16th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.9%. Chemours’s dividend payout ratio (DPR) is presently -34.31%.

Institutional Investors Weigh In On Chemours

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in Chemours in the 2nd quarter valued at approximately $477,769,000. Wolf Hill Capital Management LP bought a new stake in Chemours during the 2nd quarter worth approximately $59,698,056. Goldman Sachs Group Inc. grew its holdings in Chemours by 10.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 2,838,890 shares of the specialty chemicals company’s stock worth $38,524,000 after acquiring an additional 276,451 shares during the last quarter. Jefferies Financial Group Inc. increased its position in Chemours by 251.8% in the 3rd quarter. Jefferies Financial Group Inc. now owns 2,742,068 shares of the specialty chemicals company’s stock valued at $37,210,000 after acquiring an additional 1,962,523 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in Chemours in the 2nd quarter valued at approximately $33,353,000. Institutional investors own 76.26% of the company’s stock.

Latest Chemours News

Investors following CC have been watching these news items:

  • Negative Sentiment: Zacks Research lowered its earnings forecasts across several periods, including Q1 2027 EPS to $0.21 from $0.40, FY2027 to $1.71 from $2.05, and FY2028 to $1.98 from $2.31. The firm maintains a “Strong Sell” rating, signaling concern about Chemours’ earnings outlook.
  • Negative Sentiment: Multiple law firms announced or promoted a securities class action covering investors who acquired Chemours shares from February 20 through August 4, 2026. The complaints allege that the company misrepresented Opteon aftermarket demand amid an oversupplied refrigerant market; investors have until December 7 to seek lead-plaintiff status. The legal notices cite an earlier 18.63% share-price drop. Class action announcement
  • Negative Sentiment: One investor alert says the suit names CEO Denise Dignam and CFO Shane Hostetter and alleges they were responsible for statements about demand; it also claims the executives sold company shares during the class period. These claims remain unproven. Investor alert details

Chemours Company Profile

(Get Free Report)

The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO?) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.

Recommended Stories

Earnings History and Estimates for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.